|
|
||||||||
LETTER TO THE EDITOR |
Wageningen Centre for Food Sciences
Wageningen
The Netherlands
and
Division of Human Nutrition
Wageningen University
c/o Bomenweg 2
6703 HD Wageningen
The Netherlands
and
Institute for Health Sciences
Vrije Universiteit
Amsterdam
The Netherlands
E-mail: ingeborg.brouwer{at}wur.nl
Institute for Health Sciences
Vrije Universiteit
Amsterdam
The Netherlands
Unilever Food and Health Research Institute
Vlaardingen
the Netherlands
and
Wageningen Centre for Food Sciences
Wageningen
The Netherlands
and
Division of Human Nutrition
Wageningen University
Wageningen
The Netherlands
Dear Sir:
We appreciate the extensive and timely review of the currently available evidence on n3 fatty acids and cardiovascular disease as provided by Wang et al (1). However, they included data from our Study on Omega3 Fatty Acids and Ventricular Arrhythmia (SOFA) trial (2) that are erroneous and not to be found in any of our presentations or publications. Wang et al mistook survival rate, ie, the percentage of patients still free from disease, for event rates, ie, the percentage of patients with disease. As we reported both on the website referred to by the authors [reference 32 in the article by Wang et al (1)] and in our full publication (2), 70% of patients who received fish oil survived without ventricular fibrillation or ventricular tachycardia compared with 67% of the patients in the placebo group. The hazard ratio for the primary endpoint, patients who died or had ventricular tachycardia or ventricular fibrillation, was 0.86 (95% CI: 0.64, 1.16) and not 1.04 (0.93, 1.17) as stated by Wang et al (1). In a subgroup of 342 (not 324) patients with myocardial infarction, event-free survival (not event rate) was 72% in the fish-oil group compared with 65% in the placebo group. Patients in the SOFA trial randomly received either 2 g fish oil (n = 273, not 278), which contained
900 mg (not 2 g) very-long-chain n3 fatty acids, or 2 g (not 3.4 g) of high oleic acid sunflower oil (n = 273, not 278). Eight patients in the fish-oil group died (6 of them from cardiac causes) compared with 14 patients (13 cardiac deaths) in the placebo group (2). We would greatly appreciate if the authors would publish a corrected Table to set the record straight.
ACKNOWLEDGMENTS
None of the authors had any conflict of interest.
REFERENCES
-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006;84:517.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |